<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355858</url>
  </required_header>
  <id_info>
    <org_study_id>SCHBCC-N029</org_study_id>
    <nct_id>NCT04355858</nct_id>
  </id_info>
  <brief_title>Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer</brief_title>
  <acronym>MULAN</acronym>
  <official_title>Precision Treatment of Luminal Advanced Breast Cancer Based on Molecular Subtyping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, single-center, open-label, umbrella-shaped phase II clinical&#xD;
      study for patients with HR+/HER2- endocrine-resistant advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Seven precision treatment cohorts, which targeting NF1 mutation, gBRCA mutation,HER2&#xD;
      mutation, FDGFRb mutation PAM pathway mutations, CD8 and AR, as long as an epigenetic therapy&#xD;
      cohort and a combined immunization cohort were initially set up based on gene expression&#xD;
      profiles and molecular pathways. The main purpose is to screen valuable treatment cohorts and&#xD;
      prepare for subsequent randomized controlled phase III clinical studies with larger sample&#xD;
      size.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)</time_frame>
    <description>The proportion of participants whose best outcome is complete remission or partial remission (according to RECIST1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CBR</measure>
    <time_frame>Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)</time_frame>
    <description>the percentage of subjects with CR+PR+SD and last more than 24 weeks in all of the evaluable subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 5 years)</time_frame>
    <description>time to progressive disease (according to RECIST1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Randomization to death from any cause, through the end of study (approximately 5 years)</time_frame>
    <description>time to death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">319</enrollment>
  <condition>Breast Neoplasm</condition>
  <arm_group>
    <arm_group_label>NF1 mutated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If a patient were NF1 mutated, she would receive SHR7390(MEK1/2 inhibitor) and Faminitib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gBRCA mutated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If a patient were gBRCA mutated, she would receive SHR3162 (PARP inhibitor)and SHR6390(CDK4/6 inhibitor) .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HER2 activated mutated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If a patient were HER2 activated mutated and had not previously used capecitabine, she would receive Pyrotinib and Capecitabine , while if the patient have previously used capecitabine, she would only use pyrotinib as a single agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PDGFRb mutated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If a patient were PDGFRb mutated, she would receive Faminitib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD8 ≥10%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the arm which IHC showed CD8 ≥10%, this arm will be subdivided into 6 sub-arms, in which Arm 5A-4D, we choose the patients who had CDK4/6 inhibitor before while in Arm 5E, we choose the patients who secondarily resistant to adjuvant endocrine therapy , and in Arm 5FF, we choose the patients who is in stage IV without precious treatment or sensitively recurrence. A patient would receive SHR1210(PD-1 antibody) ,nab-paclitaxel and Faminitib in Arm-5A. A patient would receive SHR1210(PD-1 antibody) and VEGF inhibitor in Arm-5B. A patient would receive SHR1701(PD-L1/TGF-βRII inhibitor) in Arm-5C. A patient would receive SHR1701(PD-L1/TGF-βRII inhibitor) and SHR6390(CDK4/6 inhibitor) in Arm-5D. A patient would receive SHR1210(PD-1 antibody) and SHR6390(CDK4/6 inhibitor) and SERD in Arm-5E. A patient would receive SHR1210(PD-1 antibody) and SHR6390(CDK4/6 inhibitor) and AI in Arm-5F.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAM pathway mutated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If a patient had any PAM pathway mutation, she would receive Everolimus(mTOR inhibitor) combined with nab-paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AR≥10%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If a patient's IHC showed AR≥10% , she would receive SHR2554(EZH2 inhibitor) and SHR3680(AR inhibitor).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epigenetic Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this cohort, a patient would receive SHR2554(EZH2 inhibitor) and SHR3162 (PARP inhibitor).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined Immunity Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this cohort, a patient would receive SHR6390(CDK4/6 inhibitor) combined with SHR1701(anti-PD-L1/TGF-βRII bifunctional fusion protein) .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR7390</intervention_name>
    <description>MEK1/2 inhibitor</description>
    <arm_group_label>NF1 mutated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famitinib</intervention_name>
    <description>Multi-target tyrosine kinase inhibitor</description>
    <arm_group_label>CD8 ≥10%</arm_group_label>
    <arm_group_label>NF1 mutated</arm_group_label>
    <arm_group_label>PDGFRb mutated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR3162</intervention_name>
    <description>PARP inhibitor</description>
    <arm_group_label>Epigenetic Cohort</arm_group_label>
    <arm_group_label>gBRCA mutated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>HER1 / HER2 receptor tyrosine kinase inhibitor</description>
    <arm_group_label>HER2 activated mutated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>In Arm III, if the patient had not previously used capecitabine,she would receive pyrotinib and capecitabine, if the patients have previously used capecitabine, she would only used pyrotinib as a single agent.</description>
    <arm_group_label>HER2 activated mutated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR1210</intervention_name>
    <description>PD-1 antibody</description>
    <arm_group_label>CD8 ≥10%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>mTOR inhibitor</description>
    <arm_group_label>PAM pathway mutated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab paclitaxel</intervention_name>
    <description>Albumin bound paclitaxel</description>
    <arm_group_label>CD8 ≥10%</arm_group_label>
    <arm_group_label>PAM pathway mutated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR2554</intervention_name>
    <description>EZH2 inhibitor</description>
    <arm_group_label>AR≥10%</arm_group_label>
    <arm_group_label>Epigenetic Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR3680</intervention_name>
    <description>AR inhibitor</description>
    <arm_group_label>AR≥10%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR6390</intervention_name>
    <description>CDK4/6 inhibitor</description>
    <arm_group_label>CD8 ≥10%</arm_group_label>
    <arm_group_label>Combined Immunity Cohort</arm_group_label>
    <arm_group_label>gBRCA mutated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR1701</intervention_name>
    <description>anti-PD-L1/TGF-βRII bifunctional fusion protein</description>
    <arm_group_label>CD8 ≥10%</arm_group_label>
    <arm_group_label>Combined Immunity Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SERD</intervention_name>
    <description>Fulvestrant</description>
    <arm_group_label>CD8 ≥10%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AI</intervention_name>
    <description>aromatase inhibitor</description>
    <arm_group_label>CD8 ≥10%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VEGFi</intervention_name>
    <description>Bevacizumab</description>
    <arm_group_label>CD8 ≥10%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females ≥18 years old;&#xD;
&#xD;
          -  Histologically confirmed HR + / HER2- invasive breast cancer (specific definition:&#xD;
             immunohistochemical detection of ER&gt; 10% tumor cell positive is defined as ER&#xD;
             positive, PR&gt; 10% tumor cell positive is defined as PR positive, ER and / or PR&#xD;
             Positive is defined as HR positive; HER2 0-1 + or HER2 is ++ but negative followed by&#xD;
             FISH detection, no amplification, defined as HER2 negative);&#xD;
&#xD;
          -  Locally advanced breast cancer (incapable of radical local treatment) or recurrent&#xD;
             metastatic breast cancer;&#xD;
&#xD;
          -  Patients with HR+/HER2- advanced breast cancer who were previously treated with CDK4 /&#xD;
             6 inhibitor except for Arm 5E-5F;&#xD;
&#xD;
          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1&#xD;
             (RECIST v1.1)&#xD;
&#xD;
          -  Has adequate bone marrow function: absolute neutrophil count &gt; 1.5x10ˆ9 /L; platelet&#xD;
             count &gt; 75x10ˆ9 /L, hemoglobin &gt; 9g/dL;&#xD;
&#xD;
          -  Has adequate liver function: alanine aminotransferase (ALT) ≤1.5×upper limit of normal&#xD;
             (ULN), aspartate aminotransferase (AST) ≤3×ULN, alkaline phosphatase (AKP) ≤3×ULN,&#xD;
             total bilirubin (TBIL) ≤ 1.5×ULN.&#xD;
&#xD;
          -  Has adequate kidney function: serum creatinine ≤1×ULN.Endogenous creatinine clearance&gt;&#xD;
             50 ml / min (Cockcroft-Gault formula);&#xD;
&#xD;
          -  Did not receive radiation, molecular targeted therapy or surgery within 3 weeks before&#xD;
             the study began, and has recovered from the acute toxicity of previous treatment (if&#xD;
             surgery, the wound has completely healed); no peripheral neuropathy or first degree&#xD;
             peripheral neurotoxicity ;&#xD;
&#xD;
          -  ECOG score ≤ 2 and life expectancy ≥ 3 months;&#xD;
&#xD;
          -  Participants voluntarily joined the study, has signed informed consent before any&#xD;
             trial related activities are conducted, has good compliance and has agreed to&#xD;
             follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with chemotherapy, radiotherapy, immunotherapy or surgery (outpatient clinic&#xD;
             surgery excluded)within3 weeks prior to initiation of study treatment(bisphosphonates&#xD;
             can be used for bone metastasis);&#xD;
&#xD;
          -  Symptomatic, untreated, or actively progressing CNS metastases(glucocorticoids or&#xD;
             mannitol needed to control symptoms);&#xD;
&#xD;
          -  Significant cardiovascular disease(including congestive heart failure, angina&#xD;
             pectoris, myocardial infarction or ventricular arrhythmia in the last 6 months);&#xD;
&#xD;
          -  Grade ≥ 1 adverse reactions that are ongoing due to previous treatment. Exceptions to&#xD;
             this are hair loss or the investigator's opinion should not be ruled out. Such cases&#xD;
             should be clearly documented in the investigator's notes;&#xD;
&#xD;
          -  Is pregnant or breast feeding;&#xD;
&#xD;
          -  Malignant tumors in the past five years (except cured skin basal cell carcinoma and&#xD;
             cervical carcinoma in situ).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Ming Shao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhi-Ming Shao</last_name>
    <phone>86-021-64175590</phone>
    <phone_ext>8888</phone_ext>
    <email>zhimingshao@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhong-Hua Wang</last_name>
    <phone>+86 021-64175590</phone>
    <email>zhonghuawang95@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhimin Shao, MD, PhD</last_name>
      <phone>+86-021-64175590</phone>
      <phone_ext>8888</phone_ext>
      <email>zhimingshao@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>Professor, Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery</investigator_title>
  </responsible_party>
  <keyword>adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

